Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Samsung Seeks Third Anti-TNF Biosimilar Launch In Europe

Executive Summary

After receiving regulatory approvals in Europe for its biosimilar versions of etanercept and infliximab earlier this year, South Korea's Samsung Bioepis is now looking to add adalimumab to it and partner Biogen’s growing portfolio.

You may also be interested in...



Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring

Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.

Boehringer Ingelheim Throws Its Humira Biosimilar Hat Into The Ring

Boehringer Ingelheim is poised to submit marketing applications in the US and Europe for its biosimilar adalimumab after it showed equivalent safety and efficacy to Humira in a pivotal study.

Samsung Enters Oncology as Trastuzumab Accepted For EU Review

Samsung Bioepis's trastuzumab has become the South Korean company’s fifth biosimilar candidate to be filed for approval in Europe and also marks its planned entry into the oncology sector in the region.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID034708

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel